JW (Cayman) Therapeutics Co. Ltd (JWCTF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Yiping Li M.D. | Co-founder, Executive Chairman of the Board & CEO | 796.69k | -- | 1964 |
| Cao Xiaoping Ph.D. | Senior Vice President of Tech Operations | -- | -- | -- |
| Dr. Shaun Paul Cordoba Ph.D. | Senior VP & Chief Scientific Officer | -- | -- | 1980 |
| Mr. Raymond J. Hage Jr. | Senior Vice President of Corporate Development | -- | -- | 1968 |
| Mr. Qiong Wu | Senior VP & Chief Commercial Officer | -- | -- | 1974 |
| Mr. Mark J. Gilbert M.D. | Senior Advisor & Acting Chief Medical Officer | -- | -- | -- |
| Ms. Ka Man Ng A.C.I.S., A.C.S. | Company Secretary | -- | -- | 1978 |
JW (Cayman) Therapeutics Co. Ltd
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 398
Description
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Corporate Governance
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available